Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.40 |
| ▸ | WNT1 | P04628 | 12/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825019 | 0.93 | SMO (0.44) | SMODYRK1AWNT1EPHX2KCNH2 | |
| SCHEMBL12825022 | 0.90 | SMO (0.43) | SMODYRK1AEPHX2CDK9JAK2 | |
| SCHEMBL12824720 | 0.90 | SMO (0.44) | SMOEPHX2CDK9JAK2JAK1 | |
| SCHEMBL12824862 | 0.90 | SMO (0.44) | SMOEPHX2CDK9JAK2JAK1 | |
| SCHEMBL12825055 | 0.90 | SMO (0.44) | SMOEPHX2 | |
| SCHEMBL12825057 | 0.90 | SMO (0.44) | SMOEPHX2JAK2JAK1JAK3 | |
| SCHEMBL12824616 | 0.89 | SMO (0.43) | SMOEPHX2 | |
| SCHEMBL12824615 | 0.89 | SMO (0.44) | SMOEPHX2 | |
| SCHEMBL12824858 | 0.89 | SMO (0.45) | SMODYRK1AWNT1EPHX2JAK2 | |
| SCHEMBL12824594 | 0.89 | SMO (0.43) | SMOEPHX2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011024869-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2011-03-03 | — | — | WO | disclosed |